Loading clinical trials...
Loading clinical trials...
Dose Optimization and Personalized Medication Software Research of BCL-2 Inhibitor Based on Machine Learning Combined With Genomics in Patients With Acute Myeloid Leukemia
Conditions
Start Date
March 1, 2024
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2027
Last Updated
March 6, 2024
NCT06285890
NCT06220162
NCT04065399
NCT04628026
NCT06484062
NCT06994676
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions